Naslov
PLA2G4C rs1549637 polymorphism and metabolic syndrome-related parameters among patients with schizophrenia under antipsychotic treatment

Autori
Zatković, Lena ; Nadalin, Sergej ; Dević Pavlić, Sanja ; Peitl, Vjekoslav ; Karlović, Dalibor ; Rebić, Jelena ; Buretić-Tomljanović, Alena

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstract book - 12th Student Congress of Neuroscience - Neuri 2023 / Kužnik Pokorn, Jona ; Krmpotić, Rea - Rijeka, 2023, 26-27

Skup
12th Student Congress of Neuroscience - NeuRi 2023

Mjesto i datum
Rijeka, Hrvatska ; Rab, Hrvatska, 21.04.2023. - 23.04.2023

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Domaća recenzija

Ključne riječi
glucose ; lipids ; phospholipases A2, gene polymorphism ; schizophrenia

Sažetak
By playing a role in signal transduction and membrane phospholipid homeostasis, phospholipases (PLA2s) participate in a variety of physiological processes, including dopaminergic neurotransmission and insulin secretion. Patients with schizophrenia frequently exhibit abnormal signaling of dopamine and other neurotransmitters and are more likely to experience weight gain, lipid disturbances, and glucose dysregulation. Antipsychotic medication use (specifically, the use of second-generation antipsychotics) has also been linked to metabolic disturbances in schizophrenia. We previously found that rs1549637 polymorphism, an A/T polymorphism within intron 16 of the PLA2G4C gene (19q13.3), in interaction with one polymorphism of the PLA2G6 gene, predicts an elevated schizophrenia risk. We also found that PLA2G4C rs1549637 polymorphism influences the clinical expression of schizophrenia, as measured by the Positive and Negative Syndrome Scale (PANSS), in male patients. Here, we investigated whether metabolic syndrome-related parameters such as body mass index (BMI) and plasma total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, and glucose levels might be influenced by the PLA2G4C polymorphism among Croatian patients with schizophrenia under antipsychotic treatment. To our knowledge, this is the first study investigating the possible relevance of the PLA2G4C polymorphism in metabolic syndrome-related parameters. Genotyping was performed in 277 schizophrenic patients (males/females: 143/134) by polymerase chain reaction/restriction fragment length polymorphism analysis. Plasma total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, and glucose levels were determined after a 12-hour fasting period. We conducted separate analyses for males and females to account for a possible interaction of the metabolic measurements with gender. Total cholesterol and LDL cholesterol levels in females and triglyceride levels in males were elevated i.e. in the borderline high category relative to the reference values for the Croatian population, and mean BMI values were in the overweight range in both genders. Male patients manifested lower total cholesterol and HDL cholesterol levels and higher triglyceride levels than female patients (p < 0.05). The PLA2G4C polymorphism was not associated with any of the metabolic parameters among male or female patients (p > 0.05). Our results indicate that PLA2G4C polymorphism may not be of relevance in metabolic syndrome-related parameters among patients with schizophrenia under antipsychotic treatment. Environmental factors such as the use of antipsychotic medication and cigarette smoking, by modulating PLA2 activity, might have masked the effect of PLA2G4C polymorphism on metabolic syndrome-related parameters.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti, Farmacija

POVEZANOST RADA